TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01179412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% povidone-iodine
Description: apply 4 times a day for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% povidone-iodine
Description: apply 2% povidone-iodine 4 times per day for one week
Study: NCT03046368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
Study: NCT06153030

Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study: NCT02139462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard FBT training
Description: Therapists will receive standard training in Family Based Treatment (FBT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel FBT training
Description: Therapists will receive a novel training in Family Based Treatment (FBT)
Study: NCT05307718

Intervention type: DRUG
Intervention: Oral Anticoagulant, Direct-Acting
Description: Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.

Intervention type: DRUG
Intervention: Oral Anticoagulant, Direct-Acting
Description: Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.

Intervention type: DRUG
Intervention: Oral Anticoagulant, Direct-Acting
Description: Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
Study: NCT01522703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprouts
Description: 100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alfalfa Sprouts
Study: NCT04458220

Intervention type: OTHER
Intervention: photo and voice obtained
Description: The 3D face scanner and camera is used to obtain 3D or 2-dimensional portrait images of patients in different positions and from different angles.The Hi-Fi Recorder is used to obtain sound samples of patients in different word.

Intervention type: OTHER
Intervention: photo and voice obtained
Description: The 3D face scanner and camera is used to obtain 3D or 2-dimensional portrait images of patients in different positions and from different angles.The Hi-Fi Recorder is used to obtain sound samples of patients in different word.
Study: NCT03899207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training +acupressure
Description: .Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Description: Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women.
Study: NCT04255407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-ONE® therapy
Description: I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-inflammatory drug
Description: Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
Study: NCT01108692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecardiology
Description: Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telecardiology
Description: Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups.
Study: NCT02992184

Intervention type: DEVICE
Intervention: HCV RNA detection with Genedrive assay

Intervention type: DEVICE
Intervention: HCV RNA detection with Genedrive assay
Study: NCT03166046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Shortwave Therapy
Description: Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pulsed Shortwave therapy
Description: Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
Study: NCT04140266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine (DPV) Vaginal Ring (VR)-004
Description: Vaginal ring containing 25 mg of DPV
Study: NCT02992184

Intervention type: DEVICE
Intervention: HCV RNA detection with RealTime HCV
Study: NCT04140266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Tablet
Description: Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
Study: NCT00884559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instruction
Description: Debriefing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: instruction
Description: Debriefing
Study: NCT00038298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given 3 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 719
Description: 50 mg 3 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGM 719
Description: 200 mg 3 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 719
Description: 400 mg 3 times weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to AMG 719
Description: Placebo dose given 3 times weekly
Study: NCT02546505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack nutrition labeling
Description: Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack nutrition labeling
Description: Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumer information
Description: Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
Study: NCT03217461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CorneaL epithelial autograft
Description: After removal of the recipient's diseased dermoid, a size-match donor epithelial tissue will be obtained from the healthy area of the same eye (corneal epithelial autograft) using femtosecond laser technology, with the goal of closure of bare stromal area by sutured corneal epithelial tissue to ensure the integrity of ocular surface. This closure may also create a microenvironment that stimulates stromal cells' regenerative capacity and regulates their epithelial-mesenchymal transition process.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal autograft
Description: Simple dermoid excision will be performed, followed by closure of the bare sclera by sutured femtosecond laser-assisted limbal autograft.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation
Study: NCT03480295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.4% and Taurine 0.5%
Description: 4 drops /day in addition to the ongoing glaucoma treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid 0.2%
Description: 4 drops /day in addition to the ongoing glaucoma treatment
Study: NCT00184197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT01114139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo
Study: NCT01243411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
Study: NCT00244907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genistein vs Risedronate
Description: Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genistein vs Risedronate
Description: Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
Study: NCT00963443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: 2 Sachets of 500 mg Aspirin Complex.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: 2 Sachets of 500 mg Aspirin Complex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: 2 Sachets of 30 mg Pseudoephedrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: 2 Sachets of 30 mg Pseudoephedrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT05317559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: room light
Description: The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
Study: NCT01140412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg BID x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 700/100 mg BID x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg QD x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 1400/100 mg QD x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study: NCT03911362

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic Stabilisation Exercises Group
Description: Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Exercises Group
Description: The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
Study: NCT00494026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
Study: NCT01512459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine MR Capsules 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine MR Capsules 150 mg
Study: NCT03577132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant atezolizumab
Description: Atezolimumab~* At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~* Every 3 weeks, for a total of 3 cycles prior to radical cystectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant atezolizumab
Description: Atezolimumab~* At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~* Every 3 weeks, for a total of 3 cycles prior to radical cystectomy
Study: NCT02375828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
Study: NCT03061799

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HPC-03
Description: HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
Study: NCT03111615

Intervention type: DRUG
Group type: OTHER
Intervention: Aromatase Inhibitors
Description: Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated

Intervention type: DRUG
Group type: OTHER
Intervention: Aromatase Inhibitors
Description: Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated
Study: NCT03545269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CartiLife®
Description: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.
Study: NCT04707560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS fine needle biopsy with heparin wet suction
Description: EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS fine needle biopsy with heparin wet suction
Description: EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion.
Study: NCT03758105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS associated with usual care
Description: A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Medication and psychotherapy as prescribed in usual care
Study: NCT04151966

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection for markers of myocardial injury
Study: NCT04727255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaged and Resilient intervention
Description: Engaged and Resilient is a 3-phase program addressing the promotion of psychological resilience strategies for leaders.~To implement resilience training as a strategic and ethical intervention in the organization, stakeholders from Management/HR will be involved in the final design of the training program based on local institutional data, and the baseline measure result. Local training sessions will be selected from a bag-log of resilience skills structured by three general resilience factors.~To support ownership and internal sustainability, internal trainers will be educated on how to train the resilience skills in the program.~The Engaged and Resilient program consists of 20 short-term sessions for leaders based on cognitive and positive psychology.
Study: NCT01892878

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VerteLoc
Description: Single Arm
Study: NCT03462992

Intervention type: DIAGNOSTIC_TEST
Intervention: MonoMark
Description: MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
Study: NCT01329666

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks.